New MTWA technology is integrated in Quinton Q-Stress cardiac stress systems

Cambridge Heart, Inc. (OTCBB: CAMH), a developer of noninvasive diagnostic tests for cardiac disease, today announced the launch of its Microvolt T-Wave Alternans (MTWA) technology as an integrated part of industry-leading cardiac stress test systems manufactured and distributed by Cardiac Science Corporation (Nasdaq: CSCX). The MTWA technology, which can predict a patient's risk of sudden cardiac arrest (SCA), is now being offered to new and existing users of Cardiac Science's Quinton Q-Stress cardiac stress systems.

“The MTWA test is a clinically proven reimbursable test and can be performed during standard stress test sessions. It is the only test of its kind that Medicare will reimburse.”

"This is an important milestone for Cambridge Heart and a significant advancement of our new strategy to increase MTWA adoption through partnerships with cardiac diagnostic test manufacturers," said Ali Haghighi-Mood President and CEO of Cambridge Heart Inc. "The partnership with Cardiac Science, one of the world's leading manufacturers of cardiac stress test equipment, allows our technology to be marketed to a much broader number of cardiologists and internal medicine practices."

An estimated 10 to 12 million heart attack and heart failure patients in the U.S. alone could benefit from MTWA testing on an annual basis.

"MTWA for Q-Stress combines the industry's leading cardiac stress testing system with Cambridge Heart's unique testing system for SCA risk, creating the most comprehensive cardiac risk profiling system in the industry," said Tony Titus, Cardiac Science Vice President of Marketing. "The MTWA test is a clinically proven reimbursable test and can be performed during standard stress test sessions. It is the only test of its kind that Medicare will reimburse."

In an effort to make the MTWA testing more accessible, Cambridge Heart is developing OEM modules that can be integrated as an add-on to new and existing cardiac stress testing systems, cardiac monitoring devices or other devices that assess the status or risk in cardiac patients. Since the announcement of the partnership with Cardiac Science in June 2009, Cambridge Heart successfully developed and tested the OEM module, filed for and received 510K clearance from the U.S. Food and Drug Administration, completed the physical integration and sales force training within the timeframe originally projected.

"Our MTWA technology, which has proven its value as an indicator of SCA risk, can now be delivered via a modularized, software-based embodiment that makes it readily accessible, economically attractive and logistically simpler to integrate into a range of diagnostic cardiology equipment," Haghighi-Mood added.